Enlicitide vs HS-10510
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Enlicitide · Lipfendra
Marketed by Merck & Co.
NCT05952856 · Phase 3 · completed
This was a randomized, triple-blind, placebo-controlled Phase 3 trial in 2,909 adults with hypercholesterolemia. The primary endpoint was the mean percent change in LDL-C from baseline to Week 24, a standard regulator-accepted efficacy measure for lipid-lowering therapy. The active arm achieved a significantly greater LDL-C reduction than placebo (-57.1% vs +3.0%, p<0.001), so the trial met its primary endpoint with a large effect size and low risk of bias.
Next expected readout: November 2027 · NCT07821944 (registry estimate)
Reported efficacy
Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 24 (Baseline and Week 24); Number of Participants With One or More Adverse Events (AEs) (Up to 60 weeks); Number of Participants Who Discontinued Study Drug Due to an AE (Up to 52 weeks): Week 24 LDL-C mean percent change: -57.1% with enlicitide vs 3.0% with placebo; difference -55.8 percentage points (95% CI -60.9 to -50.7; p<0.001). (met)
Result source: NCT05952856
HS-10510
Developed by Hansoh Pharmaceutical Group
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Enlicitide | HS-10510 |
|---|---|---|
| LDL-C, % change | -58.2% vs 2.6%−60.8 vs placeboNCT059528696 other results
| —Not reported |
| Non-HDL-C, % change | -52.3% vs 2.1%−54.4 vs placeboNCT059528695 other results
| —Not reported |
| ApoB, % change | -48.2% vs 1.8%−50 vs placeboNCT059528695 other results
| —Not reported |
| Lp(a), % change | -24.7% vs -1.6%−23.1 vs placeboNCT059528691 other result
| —Not reported |
| 3-point MACE (% with event) | —Not posted · NCT07216482 | —Not reported |
LDL-C, % change
- Enlicitide
- -58.2% vs 2.6%−60.8 vs placeboNCT05952869
6 other results
- -64.6% vs -36.5% NCT06450366
- -55.3% vs 8.7% NCT05952869
- -59.7% vs 1.2% NCT05261126
- -57.9% vs 1.2% NCT05261126
- -54.5% vs 1.2% NCT05261126
- -40% vs 1.2% NCT05261126
- HS-10510
- —Not reported
Non-HDL-C, % change
- Enlicitide
- -52.3% vs 2.1%−54.4 vs placeboNCT05952869
5 other results
- -58% vs -31.8% NCT06450366
- -54.3% vs 1.5% NCT05261126
- -51.8% vs 1.5% NCT05261126
- -49% vs 1.5% NCT05261126
- -34.4% vs 1.5% NCT05261126
- HS-10510
- —Not reported
ApoB, % change
- Enlicitide
- -48.2% vs 1.8%−50 vs placeboNCT05952869
5 other results
- -54.6% vs -27.7% NCT06450366
- -51.8% vs 0% NCT05261126
- -48.7% vs 0% NCT05261126
- -45.8% vs 0% NCT05261126
- -32.8% vs 0% NCT05261126
- HS-10510
- —Not reported
Lp(a), % change
- Enlicitide
- -24.7% vs -1.6%−23.1 vs placeboNCT05952869
1 other result
- -26.2% vs 10.4% NCT06450366
- HS-10510
- —Not reported
3-point MACE (% with event)
- Enlicitide
- —Not posted · NCT07216482
- HS-10510
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HS-10510: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Enlicitide: 3 of 4 rows · HS-10510: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Enlicitide |
|---|---|
| Dropout rate | —20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results3% NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 1%Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.6%30 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%18 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%12 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%6 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence 11.1%Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results— NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 —30 mg NCT05261126 · Phase 2 · registry result, not featured evidence —18 mg NCT05261126 · Phase 2 · registry result, not featured evidence —12 mg NCT05261126 · Phase 2 · registry result, not featured evidence —6 mg NCT05261126 · Phase 2 · registry result, not featured evidence —Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence —Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence —Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence —Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 9.9%20 mga NCT05952856 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 11 more results4.5% NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 0%20 mg NCT06450366 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —Enlicitide NCT06450366 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 2.6%30 mg NCT05261126 · Phase 2 · registry result, not featured evidence 2.6%18 mg NCT05261126 · Phase 2 · registry result, not featured evidence 3.9%12 mg NCT05261126 · Phase 2 · registry result, not featured evidence 1.3%6 mg NCT05261126 · Phase 2 · registry result, not featured evidence 0%Panel A: Moderate Renal Impairment NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel B: Severe RI NCT05934292 · Phase 1 · registry result, not featured evidence 11.1%Panel C: End-Stage Renal Disease ( NCT05934292 · Phase 1 · registry result, not featured evidence 0%Panel D: Healthy Controls NCT05934292 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 9.4% (placebo 7.9%) influenza 8.4% (placebo 8.9%) accidental overdose 7.9% (placebo 4%) NCT05952869 · Phase 3 · monotherapy · Atherosclerotic Cardiovascular Disease · phase 3 show 9 more results30 mg covid-19 5.3% (placebo 9.3%) arthralgia 2.6% (placebo 1.3%) nausea 2.6% (placebo 0%) NCT05261126 · Phase 2 · registry result, not featured evidence 18 mg covid-19 6.6% (placebo 9.3%) nausea 5.3% (placebo 0%) diarrhoea 3.9% (placebo 1.3%) NCT05261126 · Phase 2 · registry result, not featured evidence 12 mg dyspepsia 6.6% (placebo 1.3%) arthralgia 5.3% (placebo 1.3%) fatigue 3.9% (placebo 6.7%) NCT05261126 · Phase 2 · registry result, not featured evidence 6 mg covid-19 7.8% (placebo 9.3%) diarrhoea 6.5% (placebo 1.3%) dyspepsia 1.3% (placebo 1.3%) NCT05261126 · Phase 2 · registry result, not featured evidence dry mouth 12.5% hypertension 12.5% animal bite 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 12.5% orthostatic hypotension 12.5% dry mouth 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 0% dry mouth 0% hypertension 0% NCT05934292 · Phase 1 · registry result, not featured evidence animal bite 0% dry mouth 0% hypertension 0% NCT05934292 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Enlicitide
show 6 more results
show 5 more results
show 5 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enlicitide's landscape · HS-10510's landscape